Review



13 hode  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech 13 hode
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13 Hode, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/pmc12829093-326-19-24?v=Proteintech
    Average 93 stars, based on 2 article reviews
    13 hode - by Bioz Stars, 2026-08
    93/100 stars

    Images

    1) Product Images from "Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma"

    Article Title: Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma

    Journal: Molecular Cancer

    doi: 10.1186/s12943-025-02516-2

    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing increased 13-HODE levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    Figure Legend Snippet: PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing increased 13-HODE levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5

    Techniques Used: Activity Assay, Expressing, Quantitative RT-PCR, Biomarker Discovery, Western Blot, Knockdown, ChIP-qPCR, Binding Assay, Enzyme-linked Immunosorbent Assay, Ligand Binding Assay, Co-Immunoprecipitation Assay



    Similar Products

    9 12 13 s s s trihydroxyoctadec 10eenoic acid  (Larodan)
    94
    Larodan 9 12 13 s s s trihydroxyoctadec 10eenoic acid
    9 12 13 S S S Trihydroxyoctadec 10eenoic Acid, supplied by Larodan, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/pm39110027-24-12-22?v=Larodan
    Average 94 stars, based on 1 article reviews
    9 12 13 s s s trihydroxyoctadec 10eenoic acid - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    13 hode  (Proteintech)
    93
    Proteintech 13 hode
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13 Hode, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/pmc12829093-326-19-24?v=Proteintech
    Average 93 stars, based on 1 article reviews
    13 hode - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    hydroxy 9z 11e octadecadienoic acid 13s and 13r hode  (Larodan)
    90
    Larodan hydroxy 9z 11e octadecadienoic acid 13s and 13r hode
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    Hydroxy 9z 11e Octadecadienoic Acid 13s And 13r Hode, supplied by Larodan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/pm41242694-86-10-32?v=Larodan
    Average 90 stars, based on 1 article reviews
    hydroxy 9z 11e octadecadienoic acid 13s and 13r hode - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    13(s)-hode-d4 standard  (Cayman Chemical)
    90
    Cayman Chemical 13(s)-hode-d4 standard
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13(s) Hode D4 Standard, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/pmc12272432-37-48-73?v=Cayman+Chemical
    Average 90 stars, based on 1 article reviews
    13(s)-hode-d4 standard - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    hode: 13(s)-hydroxy-octadecadienoic acid-d4  (Cayman Chemical)
    90
    Cayman Chemical hode: 13(s)-hydroxy-octadecadienoic acid-d4
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    Hode: 13(s) Hydroxy Octadecadienoic Acid D4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/bio_rxiv__2025__06__11__659216-217-37-50?v=Cayman+Chemical
    Average 90 stars, based on 1 article reviews
    hode: 13(s)-hydroxy-octadecadienoic acid-d4 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    13(s)-hode-d4  (Cayman Chemical)
    90
    Cayman Chemical 13(s)-hode-d4
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13(s) Hode D4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/pm40490052-75-45-60?v=Cayman+Chemical
    Average 90 stars, based on 1 article reviews
    13(s)-hode-d4 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    13(s)-hode gc19463  (GlpBio Technology Inc)
    90
    GlpBio Technology Inc 13(s)-hode gc19463
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13(s) Hode Gc19463, supplied by GlpBio Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/pmc12162603-94-0-2?v=GlpBio+Technology+Inc
    Average 90 stars, based on 1 article reviews
    13(s)-hode gc19463 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    acid 13 s hode  (Proteintech)
    95
    Proteintech acid 13 s hode
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    Acid 13 S Hode, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/pm39972454-270-112-171?v=Proteintech
    Average 95 stars, based on 1 article reviews
    acid 13 s hode - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    13-hydroxy-9z,11e-octadecadienoic acid, cholesteryl ester (13- hode-ce)  (Cayman Chemical)
    90
    Cayman Chemical 13-hydroxy-9z,11e-octadecadienoic acid, cholesteryl ester (13- hode-ce)
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13 Hydroxy 9z,11e Octadecadienoic Acid, Cholesteryl Ester (13 Hode Ce), supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/pm39303953-81-57-68?v=Cayman+Chemical
    Average 90 stars, based on 1 article reviews
    13-hydroxy-9z,11e-octadecadienoic acid, cholesteryl ester (13- hode-ce) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    9 10 13 s s s trihydroxyoctadec 11e enoic acid  (Larodan)
    94
    Larodan 9 10 13 s s s trihydroxyoctadec 11e enoic acid
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    9 10 13 S S S Trihydroxyoctadec 11e Enoic Acid, supplied by Larodan, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/13+hode/pm39110027-24-6-22?v=Larodan
    Average 94 stars, based on 1 article reviews
    9 10 13 s s s trihydroxyoctadec 11e enoic acid - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing increased 13-HODE levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5

    Journal: Molecular Cancer

    Article Title: Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma

    doi: 10.1186/s12943-025-02516-2

    Figure Lengend Snippet: PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing increased 13-HODE levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5

    Article Snippet: Blood samples were collected from cardiac puncture separated by centrifugation at 3000 g, 4°C, 10 min. OxLDL (Elabscience, E-EL-M0066), 13-HODE (MEIMIAN, MM-60095H2) and ANGPTL4 (Proteintech, KE00186) levels were measured using ELISA kits following the manufacturer’s instructions.

    Techniques: Activity Assay, Expressing, Quantitative RT-PCR, Biomarker Discovery, Western Blot, Knockdown, ChIP-qPCR, Binding Assay, Enzyme-linked Immunosorbent Assay, Ligand Binding Assay, Co-Immunoprecipitation Assay